CD127low expression in CD4+CD25high T cells as immune biomarker of renal function in transplant patients

Transplantation

Volumn 88, Issue SUPPL. 3, 2009, Pages

  Alonso Arias, Rebeca ^a   Suárez Alvarez, Beatriz ^a   López Vázquez, Antonio ^a   Moro, Marco A ^a   Baltar, José ^a   Gómez Huertas, Ernesto ^a   Ortega, Teresa ^a   Ortega, Francisco ^a,b   López Larrea, Carlos ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Section of Nephrology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; INTERLEUKIN 7 RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANTIGENS, CD; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CREATININE; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; REFERENCE VALUES; TACROLIMUS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 70349111117     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181afebdb     Document Type: Article

References (46)

1. Nicol D, MacDonald AS, Lawen J, et al. Early prediction of renal allo-graft loss beyond one year. Transpl Int 1993; 6: 153.
2. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
3. Paraskevas S, Kandaswamy R, Humar A, et al. Predicting long-term kidney graft survival: Can new trials be performed? Transplantation 2003; 75: 1256.
4. Takemoto SK, Terasaki PI, Gjertson DW, et al. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343: 1078.
5. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488.
6. Heeger PS, Hricik D. Immune monitoring in kidney transplant recipients revisited. J Am Soc Nephrol 2002; 13: 288.
7. Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000; 343: 1545.
8. Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5: 1971.
9. Steele DJ, Laufer TM, Smiley ST, et al. Two levels of help for B cell alloantibody production. J Exp Med 1996; 183: 699.
10. Najafian N, Salama AD, Fedoseyeva EV, et al. Enzyme-linked immunosor-bent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: Potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 2002; 13: 252.
11. Poggio ED, Clemente M, Riley J, et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 2004; 15: 1952.
12. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004; 78: 1640.
13. HutchingsA,PurcellWM,BenfieldMR.Increasedcostimulatoryresponsesin African-American kidney allograft recipients. Transplantation 2001; 71: 692.
14. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003; 3: 878.
15. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267.
16. Poggio ED, Clemente M, Hricik DE, et al. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 2006; 17: 564.
17. Poggio ED, Augustine JJ, Clemente M, et al. Pretransplant cellular al-loimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83: 847.
18. Augustine JJ, Poggio ED, Heeger PS, et al. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked im-munosorbent spots. Transplantation 2008; 86: 529.
19. Süsal C, Pelz S, Opelz G, et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650.
20. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006; 82: 663.
21. Van Gelder T, Klupp J, Kavanau K, et al. Novel mechanisms of action of mycophenolic acid (MPA): Inhibition of expression of CD28 and CD154 costimulatory molecules and induction of apoptosis in vivo in humans after treatment with mycophenolate mofetil (MMF). Transplantation 2000; 69: S393.
22. Barten MJ, Gummert JF, Van Gelder T, et al. Assessment of mechanisms of action of immunosuppressive drugs using novel whole blood assays. Transplant Proc 2001; 33: 2119.
23. Boleslawski E, BenOthman S, Grabar S, et al. CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation. Clin Transplant 2008; 22: 494.
24. Robb RJ, Munck A, Smith KA. T-cell growth factor receptors. J Exp Med 1982; 154: 1455.
25. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant T-cells. Science 1986; 232: 727.
26. Liu W, Putnam AL, Xu-yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4-T reg cells. J Exp Med 2006; 203: 1701.
27. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleu-kin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693.
28. Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4- regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007; 319: 41.
29. Codarri L, Vallotton L, Ciuffreda D, et al. Expansion and tissue infiltration of an allospecific CD4-CD25-CD45RO-IL-7Ralphahigh cell population in solid organ transplant recipients. J Exp Med 2007; 204: 1533.
30. Li J, Huston G, Swain SL. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med 2003; 198: 1807.
31. Huster KM, Busch V, Schiemann M, et al. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8- memory T cell subsets. Proc Natl Acad Sci USA 2004; 101: 5610.
32. Fuller MJ, Hildeman DA, Sabbaj S, et al. Cutting edge: emergence of CD127high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J Immunol 2005; 174: 5926.
33. Boettler T, Panther E, Bengsch B, et al. Expression of the interleukin-7 receptor - chain (CD127) on virus-specifi c CD8- T cells identifi es functionally and phenotypically defi ned memory T cells during acute resolving hepatitis B virus infection. J Virol 2006; 80: 3532.
34. Aerts NE, Dombrecht EJ, Ebo DG, et al. Activated T cells complicate the identification of regulatory T cells in rheumatoid arthritis. Cell Immu-nol 2008; 251: 109.
35. Robb RJ, Kutny RM. Structure-function relationships for the IL-2 receptor system. J Immunol 1987; 139: 855.
36. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619.
37. Waldmann TA Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol 2007: 27: 1.
38. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151.
39. Sakaguchi S. Naturally arising Foxp3-expressing CD25-CD4- regulatory T-cells in immunological tolerance to self and non-self. Nat Im-munol 2005; 6: 345.
40. Ziegler SF. FOXP3: Of mice and men. Annu Rev Immunol 2006; 24: 209.
41. Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4(-)CD25(-) T-cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303.
42. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4-CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245.
43. Jonuleit H, Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4(-)CD25(-) T-cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285.
44. Seddiki N, Santner-Nanan B, Tangye SG, et al. Persistence of naive CD45RA- regulatory T-cells in adult life. Blood 2006; 107: 2830.
45. Valmori D, Merlo A, Souleimanian NE, et al. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005; 115: 1953.
46. Sayegh MH. Why do we reject a graft? Role of indirect allorecognition in graft rejection. Kidney Int 1999; 56: 1967.